Thromboembolic And Bleeding Risks During anticoaGulant trEatment in Asian paTients With Atrial Fibrillation (TARGET-AF)

Thromboembolic and Bleeding Risk During Anticoagulant Treatment in Asian Patents With Atrial Fibrillation

Status

Enrolling by invitation

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06874894

Acronym

NOAC

Enrollment

1021

Registered

2025-03-13

Start date

2022-05-25

Completion date

2026-08-30

Last updated

2025-12-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fibrillation, Atrial

Keywords

Atrial Fibrillation, Stroke, Bleeding

Brief summary

This study was design to investigate the efficacy and safety of NOAC therapy in Koreans

Detailed description

East Asians have demonstrated a higher bleeding tendency compared to Western populations during an anticoagulation. Consequently, East Asians have been prescribed as a relatively weaker treatment regimens based on this evidence. Therefore, the TARGET-AF study aims to verify the efficacy and safety of NOAC therapy using biomarkers including TEG®-6S point-of-care device in Koreans

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Months to No maximum

Healthy volunteers

Inclusion criteria

* Patients with documented AF on 12-lead ECG, Holter monitoring, or single-lead ECG recordings are eligible for enrollment. * Based on AF treatment Korean guideline 19, AF patients who require NOAC treatment or are currently on NOAC treatment (within the past 3 months) * Adults aged 18 or above who have provided consent for clinical information

Exclusion criteria

* Patients with moderate or severe mitral stenosis or mechanical prosthetic valve

Design outcomes

Primary

Measure	Time frame	Description
Clinical ischemic and hemorrhagic events	12 months	The Rate of Ischemic stroke, systemic embolism, or myocardial infarction and ISTH (International Society on Thrombosis and Hemostasis) major/minor bleeding events

Secondary

Measure	Time frame	Description
Clinical other events	12 months	The rate of Major Adverse Cardiovascular Events: Myocardial infarction, ischemic stroke, systemic embolism, and cardiovascular death (including bleeding).

Other

Measure	Time frame	Description
COVID-19 infection	12 months	The rate of confirmation of COVID-19 infection and primary outcome

Countries

South Korea

Outcome results